Tenofovir/emtricitabine combination results in lower bone-mineral density.
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D004338:Drug Combinations; D000068679:Emtricitabine; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D063065:Organophosphonates / Q000009:adverse effects*; D000068698:Tenofovir; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D004338:Drug Combinations; D063065:Organophosphonates; D003841:Deoxycytidine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine